FAQs

What should I expect from HYMOVIS® treatment?

HYMOVIS® is intended to provide relief from your osteoarthritis knee pain when simple painkillers, exercise or physical therapy have failed to give you adequate pain relief. HYMOVIS®, a new therapy approved by the FDA, is a thick, gel-like solution that acts like a lubricant and shock absorber in the knee joint. For many patients HYMOVIS® injections may provide up to six months of relief from osteoarthritis knee pain.2,3,4

How is the HYMOVIS® therapy given?

Your doctor will inject HYMOVIS® into your knee.4

How many injections will I receive?

HYMOVIS® will be administered in a convenient two-injection regimen, with injections one week apart.2,4

How soon will I get pain relief from HYMOVIS®?

Pain relief varies from patient to patient and may depend on the severity of your disease and the intensity of your pain.2 Speak with your doctor about your concerns and expectations about HYMOVIS®.

Can I repeat my treatment with HYMOVIS®?

HYMOVIS® therapy can be safely repeated if your doctor feels it is appropriate.2 Please consult with your doctor to find out whether you can benefit from repeat treatment and when your next cycle of HYMOVIS® can be initiated.

Can I continue taking other medications when I am being treated with HYMOVIS®?

HYMOVIS® has no known drug interactions.2,3 However, you should consult with your doctor before taking any other medications while on HYMOVIS® treatment.

What do I need to do after receiving a HYMOVIS® injection?

It is recommended you avoid strenuous activities, such as high-impact sports (tennis or jogging) or prolonged weight-bearing activities (standing), for approximately 48 hours following the injection. You should speak with your doctor regarding the appropriate time to resume such activities.

Sign-up for our Newsletter!



Important Safety Information

HYMOVIS® is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy or simple analgesics (e.g., acetaminophen).

HYMOVIS® is contraindicated in patients with known hypersensitivity (allergy) to hyaluronate preparations or gram-positive bacterial proteins. Do not administer HYMOVIS® to patients with infections or skin diseases in the area of the injection site or joint.

The safety and effectiveness of the use of HYMOVIS® have not been tested in pregnant women, nursing mothers, or children. The safety and effectiveness of the use of HYMOVIS® in joints other than the knee, or for use concomitantly with other intra-articular (IA) injections, have not been established. The effectiveness of repeat treatment cycles of HYMOVIS® has not been established.

Arthralgia, transient pain, or swelling may occur after the IA injection. The incidence of arthralgia in the clinical study for HYMOVIS® was equivalent to the control group. No serious adverse events or pseudoseptic reactions were reported. Transient increases in inflammation following any IA hyaluronan injection have been reported in some patients with inflammatory joint conditions.

Strict aseptic technique should be used by licensed medical professionals trained to deliver agents into the knee joint. Joint effusion should be removed prior to injection of HYMOVIS®. Do not use disinfectants containing quaternary ammonium salts for skin preparation as hyaluronan can precipitate in their presence.

Patients should avoid strenuous or prolonged (eg, more than one hour) physical activities within 48 hours following the IA injection.

Please see Prescribing Information.

Rx Only

HYMOVIS and HYADD 4 are registered trademarks of Fidia Farmaceutici S.p.A., Abano Terme, Italy. HYMOVIS® is manufactured by Fidia Farmaceutici S.p.A., Abano Terme, Italy. ©2017 Fidia Pharma USA Inc, Florham Park, NJ 07932